Anchored in technology developed at MIT in the laboratory of its Co-Founders, Dr. Paula Hammond, LayerBio is developing novel drug delivery products for ophthalmology, wound care, tendon repair and other unmet medical needs. LayerBioâs patented platform, LayerFormâ¢, is a conformal, tunable and bioerodible polymer technology that enables coating and release of drugs from various medical devices. The product is compatible with small molecules, nucleic acids and biologic drugs and has been tested on a variety of substrates, including bandages, sutures, ophthalmic lenses and other topical and implantable devices: numerous potential applications for LayerBioâs distinctive technology. A current area of focus by the firm is development of its sustained-release formulation of the glaucoma drug travoprost. Glaucoma is the leading cause of irreversible blindness worldwide - in the US alone, an estimated 2.2 million people suffer from the disease. The typical first-line treatment for glaucoma is a topical eye drops. However, lack of continuous dosing and issues with patient compliance limit the effectiveness of topical eye drops for preventing progression of the disease - making the 24 hour sustained-release formulations an important alternative to eye drops. LayerBio's sustained-release glaucoma formulation is based on its PolyNet⢠platform - a novel network polymer-based drug delivery technology invented at LayerBio personnel. Other applications for the patented LayerForm technology would be implant and wound healing applications and drug-coated implants for cataract lens replacement that have currently to be applied as drops after s
